All In Biotech

Drug Trial Radar · NCT05537025

Study of ARO-MMP7 Inhalation Solution in Healthy Participants and Participants With Idiopathic Pulmonary Fibrosis

A Phase 1/2a Study Evaluating the Effects of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idiopathic Pulmonary Fibrosis

Last checked: Nov 20, 2026Latest source record: Aug 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 105 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

105

Actual

Start

Jan 30, 2023

Primary completion

Sep 5, 2025

Study completion Sep 5, 2025

Sponsor

Lead sponsor
Arrowhead PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Sep 13, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ARO-MMP7 in normal healthy volunteers (NHVs) and in participants with idiopathic pulmonary fibrosis (IPF). The study will initiate with NHVs receiving single ascending doses of ARO-MMP7. Following evaluation of safety and pharmacodynamic (PD) data, participants will receive multiple doses of ARO-MMP7.

Conditions

  • Idiopathic Pulmonary Fibrosis

Interventions

  • ARO-MMP7 Inhalation SolutionDrug

    ARO-MMP7 by inhalation of nebulized solution

  • PlaceboDrug

    Calculated volume of normal saline (0.9% NaCl) to match active treatment by inhalation of nebulized solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: Day 1 up to Day 85

Locations

19 sites in 6 countries. Site status is shown where the registry gives one.

  • Research Site 1

    Copenhagen, Denmark

  • Research Site 2

    Odense, Denmark

  • Research Site 1

    Ancona, Italy

  • Research Site 2

    Florence, Italy

  • Research Site 3

    Milan, Italy

  • Research Site 4

    Milan, Italy

  • Research Site 5

    Milan, Italy

  • Research Site 1

    Auckland, New Zealand

  • Research Site 2

    Christchurch, New Zealand

  • Research Site 2

    Seoul, South Korea

  • Research Site 3

    Soeul, South Korea

  • Research Site 1

    Ulsan, South Korea

  • Research Site 1

    Barcelona, Spain

  • Research Site 2

    Oviedo, Spain

  • Research Site 3

    Santander, Cantabria, Spain

  • Research Site 1

    Birmingham, United Kingdom

  • Research Site 2

    Edinburgh, United Kingdom

  • Research Site 4

    Manchester, United Kingdom

  • Research Site 3

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.